Biofrontera Inc. (NASDAQ:BFRI) Sees Large Decrease in Short Interest

Biofrontera Inc. (NASDAQ:BFRI) was the recipient of a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling 150,744 shares, a decrease of 65.5% from the February 12th total of 436,863 shares. Based on an average daily volume of 184,747 shares, the short-interest ratio is currently 0.8 days. Currently, 1.4% of the shares of the stock are sold short. Currently, 1.4% of the shares of the stock are sold short. Based on an average daily volume of 184,747 shares, the short-interest ratio is currently 0.8 days.

Analyst Ratings Changes

Separately, Benchmark reiterated a “buy” rating on shares of Biofrontera in a report on Friday, November 14th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Biofrontera currently has a consensus rating of “Hold” and an average price target of $2.75.

Institutional Trading of Biofrontera

Several large investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in Biofrontera by 54.2% in the 4th quarter. Geode Capital Management LLC now owns 65,677 shares of the company’s stock valued at $37,000 after acquiring an additional 23,074 shares during the last quarter. Rosalind Advisors Inc. grew its position in shares of Biofrontera by 51.5% in the second quarter. Rosalind Advisors Inc. now owns 976,448 shares of the company’s stock valued at $695,000 after purchasing an additional 332,055 shares in the last quarter. Finally, AIGH Capital Management LLC increased its holdings in shares of Biofrontera by 7.3% in the third quarter. AIGH Capital Management LLC now owns 1,046,050 shares of the company’s stock valued at $1,030,000 after purchasing an additional 71,525 shares during the last quarter. Hedge funds and other institutional investors own 10.08% of the company’s stock.

Biofrontera Trading Down 0.2%

BFRI stock traded down $0.00 during midday trading on Friday, reaching $0.87. The stock had a trading volume of 47,678 shares, compared to its average volume of 560,425. Biofrontera has a 52-week low of $0.54 and a 52-week high of $1.19. The company’s fifty day simple moving average is $0.86 and its 200 day simple moving average is $0.88. The company has a market cap of $10.11 million, a price-to-earnings ratio of -0.53 and a beta of 0.61.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.